Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) issued its earnings results on Wednesday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02, Zacks reports. The firm had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.

Karyopharm Therapeutics Price Performance

NASDAQ:KPTI traded down $0.01 during trading hours on Friday, hitting $0.60. 224,805 shares of the company were exchanged, compared to its average volume of 821,695. The company’s 50 day moving average price is $0.66 and its 200-day moving average price is $0.76. The stock has a market capitalization of $75.34 million, a price-to-earnings ratio of -0.59 and a beta of 0.06. Karyopharm Therapeutics has a 52-week low of $0.53 and a 52-week high of $1.70.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on KPTI. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday. Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday. Finally, StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).